

PRESS RELEASE GENEVA, OCTOBER 13, 2025

A NEW SAPONIN-CONTAINING EMULSION ADJUVANT ACCESSIBLE AT INDUSTRIAL SCALE FOR HUMAN VACCINES

The Vaccine Formulation Institute (VFI) and Seppic are pleased to announce that they are expanding their partnership to support the large-scale manufacturing and availability of a saponin-containing oil-in-water emulsion adjuvant designed for human prophylactic vaccines.

Developing safe, accessible, and effective vaccines remains a major Global Health challenge. Providing access to **openly-available and affordable adjuvant technologies to all vaccine developers** is a key response to this issue.

VFI, whose mission is to provide global access to adjuvant technologies and vaccine formulation expertise to vaccine developers worldwide, and Seppic, who develops, manufactures and supplies unique emulsion adjuvant technologies, initiated a collaboration in 2018 that led to the development and industrialization of **Sepivac SWE™**, the first open-access squalene oil-in-water adjuvant for human prophylactic vaccines. Sepivac SWE™ is now commercialized by Seppic and included in **multiple clinical studies worldwide**.

Today, VFI and Seppic reaffirm their shared commitment to global access adjuvants and confirm the industrial-scale availability of SQ, an adjuvant developed by VFI and based on the combination of a squalene oil-in-water emulsion, Sepivac™ SWE-C, industrially manufactured by Seppic and the QS-21_{DV} saponin, produced by Desert King International.

SQ is currently available from VFI at GMP grade for evaluation in preclinical and clinical studies. This new advance in the strategic alliance between VFI and Seppic will contribute to large-scale, global availability of SQ adjuvant for the development of commercial vaccines.

Saponin-containing adjuvants have been shown to be instrumental in the development and success of new vaccines, in particular towards diseases of Global Health importance, such as Malaria or Tuberculosis, which makes this development a path to innovation for the future of healthcare.

Nicolas Collin, VFI Co-founder and CEO, explained: "The broad access to safe and efficacious adjuvants is still a major issue for vaccine developers worldwide. Partnering with Seppic and Desert King International will support the large-scale availability in open-access of VFI's SQ adjuvant, and the development of new vaccines for Global Health."

Hannes Moeller, Managing Director of Seppic, stated: "With this new development, Seppic is strengthening the strategic partnership it began several years ago with VFI. By putting our innovation and industrial capabilities at the service of the vaccine community, including a GMP production unit dedicated to vaccine adjuvants, we aim at contributing to advancing the health of everyone, everywhere."

PRESS RELEASE GENEVA, OCTOBER 13, 2025**CONTACTS:** contact@vformulation.org / media-seppic@airliquide.com**VFI IN BRIEF**

VFI is a company based in Geneva, Switzerland, with over 13 years of experience in adjuvant development and vaccine formulation. VFI's mission is to facilitate global access to adjuvants and vaccine formulation know-how, by driving innovative research in adjuvants and vaccine formulation, and supporting preclinical and clinical development for vaccine developers and manufacturers worldwide. Over the past decade, VFI has built a portfolio of emulsion- and liposome-based adjuvants that are available under open access terms. www.vaccineformulationinstitute.org

SEPPIC IN BRIEF

A subsidiary of Air Liquide Healthcare, Seppic designs, produces and distributes a wide range of specialty ingredients used in cosmetics, nutraceuticals, pharmaceuticals, veterinary and industrial products. Seppic employs nearly 900 people, including 110 dedicated to innovation, and supports its customers in 100 countries through its subsidiaries and network of distributors. Thanks to a committed approach to research and innovation, focused on serving its stakeholders, Seppic works every day to put science at the service of all: Seppic, science that cares.

AIR LIQUIDE HEALTHCARE IN BRIEF

Air Liquide Healthcare is a world leader in medical gases, home healthcare services and specialty ingredients. Our 15,600 employees support 2.1 million chronic patients and provide medical gases and related services to 20,000 hospitals and new care facilities, as well as 140,000 healthcare professionals. Committed to working alongside professionals and health institutions, our patient-centered approach is based on the principles of Value-based Healthcare, which aims to improve the benefits experienced by patients, at the best cost to society, thus contributing to a more efficient and virtuous system.